Navigation Links
Watson Receives FTC Clearance for Arrow Acquisition
Date:12/2/2009

MORRISTOWN, N.J., Dec. 2 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the Federal Trade Commission (FTC) has accepted a proposed consent order for public comment relating to Watson's pending acquisition of privately held Arrow Group and has granted early termination of the Hart Scott Rodino waiting period, thereby permitting the parties to close the transaction. The parties have now obtained all regulatory approvals required to close the transaction. Accordingly, the parties expect to consummate the acquisition of Arrow by Watson today.

Under the terms of a consent order with the FTC, Watson and Arrow have agreed to the following conditions to complete the transaction:

  • Watson will sell to Impax Laboratories, Inc. its Abbreviated New Drug Application (ANDA) for Cabergoline, the generic equivalent to Dostinex®.
  • Cobalt Pharmaceuticals, Inc. will sell to Impax Laboratories, Inc. its pending ANDA for Dronabinol, a generic equivalent to Marinol®.
  • Resolution Chemicals Ltd. (Resolution), the subsidiary of the Arrow Group that manufactures Dronabinol active pharmaceutical ingredient, and that will supply finished Dronabinol product to Impax Laboratories upon approval, will be sold to existing management of Resolution Holdings and divested from the Arrow Group immediately prior to the closing. Resolution has entered into an agreement with Impax Laboratories to supply finished Dronabinol product.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Watson Completes Acquisition of Arrow Group
2. Employers Plan to Increase Use of Self-Service Decision-Making Technology For Open Enrollment, Watson Wyatt Survey Finds
3. Watson Names G. Frederick Wilkinson Executive Vice President, Global Brands
4. Watson Pharmaceuticals Receives FDA Approval for Generic PLAN B(R) for Over-the-Counter Use
5. Watson Prices $850 Million of Senior Unsecured Notes
6. Watson Announces Limited Recall Of Fentanyl Transdermal System
7. Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
8. Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
9. Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
10. Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
11. Watson CFO Mark W. Durand to Take Leave of Absence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2014)... Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced today that ... CDX-1401 in solid tumors, including long-term patient follow-up, ... (Vol 6 Issue 232). The data demonstrate ... of clinical benefit in patients with very advanced ... to better outcomes on subsequent therapy with checkpoint ...
(Date:4/16/2014)... According to a new study, endoscopists, recommendations for ... to two small polyps are consistent with guideline recommendations ... an appropriate target for quality indicators. This is the ... guidelines for timing of repeat colonoscopy after one to ... average-risk patients. The study appears in the April issue ...
(Date:4/15/2014)... diabetes and pre-diabetes in the United States have nearly ... Hopkins Bloomberg School of Public Health, with obesity apparently ... that the burden of the disease has not hit ... blacks, Hispanics and the elderly. , According to new ... the Annals of Internal Medicine , diabetes increased ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found ... which kill about 1.5 million people a year. The researchers ... an antifungal drug that has been in use for more ... toxic to human cells as it is to the microbes ... findings appears in Nature Chemical Biology . , "Invasive ...
(Date:4/15/2014)... Diego School of Medicine have identified a mechanism that ... liver disease and why the virus is able to ... The hard-to-kill pathogen, which infects an estimated 200 million ... the mitochondria dismantling the cell,s innate ability to ... dynamics. , The study, published in today,s issue of ...
Breaking Medicine News(10 mins):Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 2Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 3Health News:Celldex's Phase 1 study of CDX-1401 published in Science Translational Medicine 4Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 2Health News:Surveillance colonoscopy recommendations for average-risk patients with 1 to 2 small polyps consistent with guidelines 3Health News:Pre-diabetes and diabetes nearly double over the past 2 decades 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Breaking bad mitochondria 2
... CHAPEL HILL, N.C., Nov. 2 With ... the manufacturing environment, best-in-class,companies continue to focus ... internal and external customer relationships. In reviewing,the ... more,than three-quarters of the benchmark class posts ...
... 2 Addressing more than,100 cardiologists and other ... and CEO, set out four critical priorities for,improving ... at,Schering-Plough,s fourth annual Cardiovascular Summit in advance of ... In his speech, Hassan emphasized the potential for ...
... Hair to Help ... Women with Cancer, CINCINNATI, Nov. 2 Two-time Oscar winner,Hilary ... of support for women with cancer. This national campaign,encourages people to ... create free wigs for women who have lost their hair due ...
... Recent outbreaks of,antibiotic-resistant Staphylococcus aureus, more commonly known as ... healthy people,can carry on the skin or nose, it is ... the skin, in the blood, in the bones and,in the ... of antibiotics.,While most of these infections are minor, some however, ...
... Icon Supports Bargaining for Improved Patient Care, HUNTINGTON ... and co-founder of the United Farm Workers of,America, will ... Park for a walkthrough to shed light on patient ... year, caregivers have been seeking a new contract at,the ...
... Technique just as effective in patients under 60, study finds ... known as brachytherapy, are just as effective for treating prostate ... older men, a new study finds. , Brachytherapy is ... placed in the prostate to kill cancer cells. Recovery time ...
Cached Medicine News:Health News:Manufacturing Organizations Identify Efficiencies in Credit and Collections Functions 2Health News:Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 2Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 3Health News:Hilary Swank Donates Her Hair to Pantene(R) Beautiful Lengths(TM) 4Health News:Radiation Seed Treatment Helps Younger Men Fight Prostate Cancer 2
(Date:1/15/2014)... 2014  Novation, the leading health care supply ... new IT value-added reseller (VAR) national contracts that ... IT goods and services at lower costs. These ... as value-added services such as initiative assistance and ... Novation agreements were awarded to CDW Government, Paragon ...
(Date:1/15/2014)... 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ... dermatology for clinical and aesthetic dermatology practitioners in the ...
(Date:1/15/2014)... Jan. 15, 2014 Tegra Medical is very ... Mark King as its new Chief Executive Officer.  ... Operating Officer, in which he has overseen the company,s ... Mississippi , and Costa Rica.  Mr. King ... broad-based operations, sales, engineering and manufacturing experience in medical ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... With 30 Installed Inveon Imaging Systems, Siemens ... Position in Preclinical Imaging Centers, HOFFMAN ... adage,says "a picture is worth 1,000 words," ... research where high-resolution images can validate years ...
... Results Seen Since Presentation ... to Include Alvespimycin Plus Trastuzumab Plus ... Paclitaxel Regimen, HAYWARD, ... data from a Phase 1 clinical,trial showing that alvespimycin, its second-generation Hsp90 ...
Cached Medicine Technology:Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 2Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 3Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 4Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission 5Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 2Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 3Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 4Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial 5
... Freedom leg bags are part ... a versatile line of leg bags, ... the varied needs of our customers. ... several sizes, and constructed of 100% ...
... part of the Freedom Urinary Collection ... bags, kits, and accessories designed to ... customers. These leg bags are offered ... 100% latex-free soft, textured medical grade ...
... are part of the Freedom Urinary ... leg bags, kits, and accessories designed ... our customers. These leg bags are ... of 100% latex-free soft, textured medical ...
The latex-free, PVC-free Antibacterial Hydro Personal catheter combines two remarkable innovations into one exclusive catheter that delivers an antibacterial agent while providing the virtually frict...
Medicine Products: